title: The treatment of intractable rejection with tacrolimus (FK506) in pediatric liver transplant recipients.
abstract: We report our experience in 17 pediatric orthotopic liver transplant (OLT) patients converted from cyclosporine (CsA) to FK506 for intractable acute and chronic rejection. FK506 was initiated orally at a dose of 0.3 mg/kg/day in most patients; the dose was then adjusted to achieve serum levels of 0.5-1.5 ng/ml. Azathioprine was discontinued and low-dose prednisone maintained. The median time between liver transplantation and FK506 conversion was 41 months. Patients have been treated for an average of 14.8 +/- 9.6 months. Six patients were converted for acute rejection and 11 for chronic rejection, i.e., vanishing bile duct syndrome (VBDS). After FK506 conversion, the actual patient and graft survival was 88% and 82%, respectively, in the group as a whole. Two patients died, one of chronic active hepatitis C and the other of lymphoma. Three patients, all with VBDS, did not respond to FK506 and therefore required retransplantation. The serum bilirubin is currently normal in 14 patients and the serum transaminases < 100 IU/ml in 12. The mean bilirubin pre-FK506 of patients successfully converted to FK506 was 4.2 mg/dl compared to 11.8 mg/dl in patients who failed conversion. Major complications included nephrotoxicity, neurotoxicity, and lymphoma. The mean glomerular filtration rate (GFR) of 97 +/- 29 mls/min/1.73m2 prior to FK506 conversion dropped to 51 +/- 20 mls/min/1.73m2 (p = 0.0001) after a mean of 13.6 months of FK506 therapy. Three patients have developed B-cell lymphomas; two of them responded to decreased immunosuppression and one died. We conclude that intractable liver graft rejection in children is most successfully reversed if FK506 is instituted before cholestasis becomes pronounced.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: UCLA-Dumont Transplant Center, UCLA Medical Center 90024-1752, USA.
authors.forename: S V
authors.initials: SV
authors.lastname: McDiarmid
authors.forename: P
authors.initials: P
authors.lastname: Wallace
authors.forename: J
authors.initials: J
authors.lastname: Vargas
authors.forename: M E
authors.initials: ME
authors.lastname: Ament
authors.forename: R W
authors.initials: RW
authors.lastname: Busuttil
mesh_terms: D000284:Administration, Oral; D001663:Bilirubin / Q000097:blood; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use; D006084:Graft Rejection / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D007223:Infant; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000378:metabolism / Q000473:pathology; D008113:Liver Neoplasms / Q000139:chemically induced; D016031:Liver Transplantation / Q000009:adverse effects* / Q000276:immunology; D016393:Lymphoma, B-Cell / Q000139:chemically induced; D011241:Prednisone / Q000627:therapeutic use; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D016572:Cyclosporine; D001663:Bilirubin; D011241:Prednisone; D016559:Tacrolimus